Skip to main content
Erschienen in: Current Breast Cancer Reports 1/2015

01.03.2015 | Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Axillary Node Management in Patients Receiving Neoadjuvant Chemotherapy

verfasst von: Leopoldo J. Fernandez, Harry D. Bear

Erschienen in: Current Breast Cancer Reports | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Neoadjuvant chemotherapy (NAC) has increasingly been used to allow breast conservation, without compromising survival or local control. NAC can also downstage nodal status in about 40 % of women with positive nodes (cN+). Concurrently, primary surgical management of the axilla has transitioned towards sentinel lymph node biopsy (SLNB) as the preferred alternative to axillary lymph node dissection (ALND) for clinically node-negative patients. Although some still support SLNB prior to NAC for node-negative breast cancer, the use of SLNB after NAC has become an increasingly accepted practice. SLNB after NAC for node-positive breast cancer has remained more controversial. Recent trials show that the false-negative rates for SLNB after NAC for women presenting with positive nodes are approximately 10 % when two tracers are used for mapping and two or more SLNs are examined. This review summarizes the available evidence and rationale regarding management of regional nodes in women receiving NAC.
Literatur
1.
Zurück zum Zitat Untch M et al. Current and future role of neoadjuvant therapy for breast cancer. Breast. 2014;23(5):526–37.CrossRefPubMed Untch M et al. Current and future role of neoadjuvant therapy for breast cancer. Breast. 2014;23(5):526–37.CrossRefPubMed
2.
Zurück zum Zitat Fisher B et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–85.PubMed Fisher B et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–85.PubMed
3.
Zurück zum Zitat Gianni L et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11(24 Pt 1):8715–21.CrossRefPubMed Gianni L et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11(24 Pt 1):8715–21.CrossRefPubMed
4.
Zurück zum Zitat Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188–94.CrossRefPubMed Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188–94.CrossRefPubMed
5.
Zurück zum Zitat Fisher B et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.CrossRefPubMed Fisher B et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.CrossRefPubMed
6.
Zurück zum Zitat Krag DN et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–8.CrossRefPubMed Krag DN et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–8.CrossRefPubMed
7.
Zurück zum Zitat Black DM et al. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg. 2014;149(8):788–96.CrossRefPubMed Black DM et al. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg. 2014;149(8):788–96.CrossRefPubMed
8.
Zurück zum Zitat Ashikaga T et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.CrossRefPubMedCentralPubMed Ashikaga T et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569–75.CrossRefPubMed Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569–75.CrossRefPubMed
10.
Zurück zum Zitat Koolen BB et al. Early assessment of axillary response with (1)(8)F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227–35.CrossRefPubMed Koolen BB et al. Early assessment of axillary response with (1)(8)F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227–35.CrossRefPubMed
11.
Zurück zum Zitat Park S et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis. Ann Surg Oncol. 2013;20(9):2858–65.CrossRefPubMed Park S et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis. Ann Surg Oncol. 2013;20(9):2858–65.CrossRefPubMed
12.
Zurück zum Zitat Hieken TJ et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20(10):3199–204.CrossRefPubMed Hieken TJ et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20(10):3199–204.CrossRefPubMed
13.•
Zurück zum Zitat Boughey JC. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. Jama. 2013;310(14):1455–61. In patients with breast cancer presenting with positive axillary nodes who undergo NAC, the SLN detection rate was improved when two mapping agents (Blue dye and Radioactive Colloid) were used, and the FNR was 10.8% with two mapping agents and less than 10% when more than 2 LNs were identified.CrossRefPubMedCentralPubMed Boughey JC. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. Jama. 2013;310(14):1455–61. In patients with breast cancer presenting with positive axillary nodes who undergo NAC, the SLN detection rate was improved when two mapping agents (Blue dye and Radioactive Colloid) were used, and the FNR was 10.8% with two mapping agents and less than 10% when more than 2 LNs were identified.CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Dominici LS et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116(12):2884–9.CrossRefPubMed Dominici LS et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116(12):2884–9.CrossRefPubMed
15.
Zurück zum Zitat Im SA et al. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07–01. Breast Cancer Res Treat. 2012;132(2):589–600.CrossRefPubMed Im SA et al. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07–01. Breast Cancer Res Treat. 2012;132(2):589–600.CrossRefPubMed
16.
Zurück zum Zitat Overgaard M et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.CrossRefPubMed Overgaard M et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.CrossRefPubMed
17.
Zurück zum Zitat Ragaz J et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–62.CrossRefPubMed Ragaz J et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–62.CrossRefPubMed
18.
Zurück zum Zitat Overgaard M et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–8.CrossRefPubMed Overgaard M et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–8.CrossRefPubMed
19.
Zurück zum Zitat McGale P et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRefPubMed McGale P et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRefPubMed
20.
Zurück zum Zitat Bear HD et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019–27.CrossRefPubMed Bear HD et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019–27.CrossRefPubMed
21.
Zurück zum Zitat von Minckwitz G et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.CrossRef von Minckwitz G et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.CrossRef
22.•
Zurück zum Zitat Cortazar P. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. Pooled analysis of 12 international trials including 11,955 patients shows that pCR of both tumor (ypT0 or ypTis) and LNs (ypN0) after NAC was associated with improved survival, and the prognostic value was greatest for aggressive tumor subtypes.CrossRefPubMed Cortazar P. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. Pooled analysis of 12 international trials including 11,955 patients shows that pCR of both tumor (ypT0 or ypTis) and LNs (ypN0) after NAC was associated with improved survival, and the prognostic value was greatest for aggressive tumor subtypes.CrossRefPubMed
23.•
Zurück zum Zitat Mamounas EP. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6. For patients treated with NAC, the risk of LRR can be estimated based on patient age, the tumor characteristics before NAC and the nodal status after NAC (ypN). Despite the omission of post-operative irradiation to the regional nodes or chest wall, patients presenting with clinically positive nodes but with pathologically negative nodes after NAC had low regional recurrence rates.CrossRefPubMedCentralPubMed Mamounas EP. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6. For patients treated with NAC, the risk of LRR can be estimated based on patient age, the tumor characteristics before NAC and the nodal status after NAC (ypN). Despite the omission of post-operative irradiation to the regional nodes or chest wall, patients presenting with clinically positive nodes but with pathologically negative nodes after NAC had low regional recurrence rates.CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Khan A et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005;12(9):697–704.CrossRefPubMed Khan A et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005;12(9):697–704.CrossRefPubMed
25.•
Zurück zum Zitat Kuehn T. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18. For patients presenting with clinically negative (cN0) nodes and pathologically positive SLN before NAC, SLN detection rate was low and FNR was unacceptably high if a repeat SLNB was attempted after NAC (arm B).CrossRefPubMed Kuehn T. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18. For patients presenting with clinically negative (cN0) nodes and pathologically positive SLN before NAC, SLN detection rate was low and FNR was unacceptably high if a repeat SLNB was attempted after NAC (arm B).CrossRefPubMed
26.
Zurück zum Zitat Rutgers E.J.; Donker M., S.M.E., Meijnen P., Van De Velde C.J.H., Mansel R.E., Westenberg H., Orzalesi L., Bouma W.H., van der Mijle H., Nieuwenhuijzen G.A.P., Veltkamp S.C., Slaets L., Messina C.G.M., Duez N.J., Hurkmans C., Bogaerts J., van Tienhoven G., Radiotherapy of surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). Journal of Clinical Oncology (Supplement; abstract number LBA 1001), 2013. 31. Rutgers E.J.; Donker M., S.M.E., Meijnen P., Van De Velde C.J.H., Mansel R.E., Westenberg H., Orzalesi L., Bouma W.H., van der Mijle H., Nieuwenhuijzen G.A.P., Veltkamp S.C., Slaets L., Messina C.G.M., Duez N.J., Hurkmans C., Bogaerts J., van Tienhoven G., Radiotherapy of surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). Journal of Clinical Oncology (Supplement; abstract number LBA 1001), 2013. 31.
27.
Zurück zum Zitat Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001;182(4):312–5.CrossRefPubMed Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001;182(4):312–5.CrossRefPubMed
28.
Zurück zum Zitat Xing Y et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93(5):539–46.CrossRefPubMed Xing Y et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93(5):539–46.CrossRefPubMed
29.
Zurück zum Zitat Kelly AM et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16(5):551–63.CrossRefPubMed Kelly AM et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16(5):551–63.CrossRefPubMed
30.
Zurück zum Zitat van Deurzen CH et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45(18):3124–30.CrossRefPubMed van Deurzen CH et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45(18):3124–30.CrossRefPubMed
31.
Zurück zum Zitat Patel NA et al. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am Surg. 2004;70(8):696–9. discussion 699–700.PubMed Patel NA et al. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am Surg. 2004;70(8):696–9. discussion 699–700.PubMed
32.
Zurück zum Zitat Mamounas EP et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694–702.CrossRefPubMed Mamounas EP et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694–702.CrossRefPubMed
33.
Zurück zum Zitat Krag D et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998;339(14):941–6.CrossRefPubMed Krag D et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998;339(14):941–6.CrossRefPubMed
34.
Zurück zum Zitat Veronesi U et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.CrossRefPubMed Veronesi U et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.CrossRefPubMed
35.
Zurück zum Zitat McMasters KM et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18(13):2560–6.PubMed McMasters KM et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18(13):2560–6.PubMed
36.
Zurück zum Zitat Hunt KK et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558–66.PubMed Hunt KK et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558–66.PubMed
37.
Zurück zum Zitat Shen J et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007;109(7):1255–63.CrossRefPubMed Shen J et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007;109(7):1255–63.CrossRefPubMed
38.
Zurück zum Zitat Gimbergues P et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008;15(5):1316–21.CrossRefPubMed Gimbergues P et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008;15(5):1316–21.CrossRefPubMed
39.
Zurück zum Zitat Boileau, J.F.P., B.; Basik, M.; Holloway, C.; Gaboury, L.; Sideris, L.; Meterissian, S.H.; Arnaout, A.; Brackstone, M.; McCready, D.R.; Karp, S.E.; Wright, F.C.; Younan, R.; Provencehr, L.; Patocskai, E.; Omeroglu, A.; Robidoux, A., Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer: The SN FNAC study. J Clin Oncol, 2013. 31 (suppl; abstr 1018). Boileau, J.F.P., B.; Basik, M.; Holloway, C.; Gaboury, L.; Sideris, L.; Meterissian, S.H.; Arnaout, A.; Brackstone, M.; McCready, D.R.; Karp, S.E.; Wright, F.C.; Younan, R.; Provencehr, L.; Patocskai, E.; Omeroglu, A.; Robidoux, A., Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer: The SN FNAC study. J Clin Oncol, 2013. 31 (suppl; abstr 1018).
40.
Zurück zum Zitat Olivotto IA et al. A clinical trial of breast radiation therapy versus breast plus regional radiation therapy in early-stage breast cancer: the MA20 trial. Clin Breast Cancer. 2003;4(5):361–3.CrossRefPubMed Olivotto IA et al. A clinical trial of breast radiation therapy versus breast plus regional radiation therapy in early-stage breast cancer: the MA20 trial. Clin Breast Cancer. 2003;4(5):361–3.CrossRefPubMed
Metadaten
Titel
Axillary Node Management in Patients Receiving Neoadjuvant Chemotherapy
verfasst von
Leopoldo J. Fernandez
Harry D. Bear
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 1/2015
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-014-0168-6

Weitere Artikel der Ausgabe 1/2015

Current Breast Cancer Reports 1/2015 Zur Ausgabe

Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Surgical Strategies for Prevention and Treatment of Lymphedema in Breast Cancer Patients

Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Surgical Management of Hereditary Breast Cancer

Local-Regional Evaluation and Therapy (KK Hunt, Section Editor)

Intraoperative Radiotherapy: Is it Ready for Prime Time?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.